Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel therapy with orphan drug indication for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. The company was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.

Company Data

Name Cadrenal Therapeutics, Inc. - Common Stock

Company Cadrenal Therapeutics, Inc. Common Stock

Symbol CVKD

Website https://www.cadrenal.com

Primary Exchange

NASDAQ

ISIN US1276361086

Asset Class Share

Sector Healthcare

Industry Biotechnology

CEO Quang X. Pham

Market Capitalization 22 Mio

Country United States of America

Currency USD

Employees 0,0 T

Address 822 A1A North, 32082 Ponte Vedra

IPO Date 2023-01-20

Stock Splits

Date	Split
20.08.2024	1:15

Ticker Symbols

Name	Symbol
NASDAQ	CVKD

More Shares

Investors who hold Cadrenal Therapeutics, Inc. - Common Stock also have the following shares in their portfolio:

SPAREBK 1 BOLIG.11/21 MTN Bond

VANECK POLKADOT ETN29 ETN

The financial platform MoneyPeak tracks and analyzes investments and portfolios. From securities portfolios to crypto purchases.
Useful, simple, and free. Stocks, ETFs, ETCs, ETNs, indices, funds, bonds, certificates, currencies, options, rights issue.

Imprint Data Protection Blog Community Feedback Changelog